Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review
Pharmacology
[키워드] Affect
article
articles
blockade
Characteristics
clinical
CNKI
Cochrane Library
conducted
controlled trials
coronavirus disease
Coronavirus disease 2019 (COVID-19)
COVID-19
COVID-19 patient
Critically ill
Cytokine storm
Diagnostic Criteria
edge
Efficacy and safety
evaluated
Evidence
exclusion criteria
Final
GM-CSF
GM-CSF blockades
Health
high mortality
identify
IL-6 inhibitors
Inclusion
Inflammatory response
inhibitors
interleukin (IL)-1
interleukin-1
Meta-analysis
Mortality
multiple organ dysfunction
Odds ratio
Other
outcomes
pandemic
Patient
patients treated
patients with COVID-19
people with COVID-19
protocol
reduce
Registration
Regulation
released
resource
review
risk
SAE
SAEs
sarilumab
SARS-CoV-2
Secondary infection
secondary infections
Sepsis
Serious Adverse Event
significantly
Specific
specific interleukin-1 inhibitors
specific interleukin-6 inhibitors
statistical significance
syndrome
systematic review
Tocilizumab
Treatment
was performed
[DOI] 10.3389/fphar.2021.804250 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2021.804250 PMC 바로가기 [Article Type] Pharmacology